At a glance
ClinicalIndex Comparison RecordPhase 2Withdrawn· 0 enrolled
Drug / intervention
Decitabinedrug
Likely dose
Decitabine 20mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Efficacy of Decitabine in Clearance of MRD
Institute of Hematology & Blood Diseases Hospital, China·interventional·Posted Jan 13, 2017·Updated May 30, 2025
In Brief
A Phase 2 clinical trial evaluating Decitabine for AML. Withdrawn before enrollment, across 1 site.
Signals
Trial was withdrawn before enrollment
Detailed Summary
In this open-label, prospective clinical trial, the investigators enrolled acute myeloid leukemia (AML) patients after consolidation therapy. Patients with minimal residual disease (MRD) receive decitabine treatment if patients do not receive stem cell transplantation. The MRD clearance rate is the primary outcome to measure the efficacy of decitabine regimen.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAML
CountriesChina
Collaborators--
Timeline
Phase 2WithdrawnFinished
2017201820192020202120222023202420252026
First PostedJan 2017
Enrollment StartFeb 2017
Primary CompletionDec 2021
Study CompletionDec 2022
TodayJul 2026
First PostedJan 13, 2017
Enrollment StartFeb 8, 2017
Primary CompletionDec 1, 2021
Study CompletionDec 1, 2022
TodayJul 1, 2026
Enrollment to primary: 4.8 yearsPosted 9.5 years ago
Interventions
Decitabinedrug
Decitabine at a dose of 20mg/㎡/d on day 1-5.